Strongbridge Biopharma (SBBP) Tops Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. MRNA
2. KEYS
3. KLAR
4. PANW
5. SPY
6. MRK
7. HD
8. DVLT
9. NBIS
10. AMLX

Go back to Strongbridge Biopharma (SBBP) Tops Q1 EPS by 12c

Strongbridge Biopharma (SBBP) Acquires U.S. Rights to KEVEYIS

December 23, 2016 8:08 AM EST

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has acquired the U.S. rights to KEVEYIS® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (Taro). KEVEYIS was approved by the U.S. Food and Drug Administration (FDA) in August 2015 to treat hyperkalemic, hypokalemic, and related variants of... More

Strongbridge Biopharma (SBBP) Enters $35M Securities Purchase Agreement

December 23, 2016 8:06 AM EST

Strongbridge Biopharma plc, (Nasdaq: SBBP) today announced that it has entered into a definitive securities purchase agreement for a placement of its ordinary shares and warrants, which is expected to generate total gross proceeds to the Company of $35 million. The financing is being led by CAM Capital and Vivo Capital, with additional participation from Broadfin Capital, Boxer Capital of the Tavistock Group and HealthCap, as well as several new and existing institutional and individual investors. Stifel is acting as the lead... More